Deep Brain Stimulation of the Centromedian Nucleus of the Thalamus for Lennox-Gastaut Syndrome: A Systematic Review and Individual Patient Data Analysis.
Journal
Neurosurgery
ISSN: 1524-4040
Titre abrégé: Neurosurgery
Pays: United States
ID NLM: 7802914
Informations de publication
Date de publication:
01 04 2023
01 04 2023
Historique:
received:
04
07
2022
accepted:
29
09
2022
pubmed:
27
1
2023
medline:
21
3
2023
entrez:
26
1
2023
Statut:
ppublish
Résumé
Lennox-Gastaut syndrome (LGS) is a severe childhood-onset pharmacoresistant epilepsy. Deep brain stimulation (DBS) of the centromedian nucleus of the thalamus (CMN) has been utilized. To conduct a systematic review and individual patient data (IPD) analysis to characterize outcomes of DBS of CMN in LGS. PubMed, Embase, and Scopus were searched per Preferred Reporting Items for Systematic Reviews and Meta-Analyses. Articles were screened by title/abstract then full text. Included articles were reviewed for bibliographic, demographic, and outcome data. IPD were extracted from studies providing IPD for all patients. Of 72 resultant articles, 10 studies (114 patients) were included. Six of 7 studies reporting the outcome of ≥50% seizure reduction indicated that ≥50% of patients achieved this, with improved functional ability. Seizure freedom rate was generally <10%. Six studies with 47 patients provided IPD. The mean ages at epilepsy onset and CMN DBS were 3.9 ± 4.5 years and 17.4 ± 8.8 years, respectively. Nineteen of 41 (46.3%) patients had positive MRI findings. Seizure types included atypical absence in 39 (83.0%) patients, generalized tonic-clonic in 32 (68.1%), tonic in 22 (46.8%), and atonic in 20 (42.6%). Thirty-eight (80.9%) patients experienced ≥50% reduction in seizure frequency, and only 3 (6.4%) experienced seizure freedom. The mean seizure reduction was 62.9% ± 31.2% overall. Quality of life improved in 30/34 (88.2%) and was unchanged in the remainder (11.8%). The complication rate was 2/41 (4.9%). The mean length of follow-up was 19.8 ± 26.1 months (IQR: 4-18 months). Limited data indicate that DBS of the CMN may be effective and safe for people with LGS.
Sections du résumé
BACKGROUND
Lennox-Gastaut syndrome (LGS) is a severe childhood-onset pharmacoresistant epilepsy. Deep brain stimulation (DBS) of the centromedian nucleus of the thalamus (CMN) has been utilized.
OBJECTIVE
To conduct a systematic review and individual patient data (IPD) analysis to characterize outcomes of DBS of CMN in LGS.
METHODS
PubMed, Embase, and Scopus were searched per Preferred Reporting Items for Systematic Reviews and Meta-Analyses. Articles were screened by title/abstract then full text. Included articles were reviewed for bibliographic, demographic, and outcome data. IPD were extracted from studies providing IPD for all patients.
RESULTS
Of 72 resultant articles, 10 studies (114 patients) were included. Six of 7 studies reporting the outcome of ≥50% seizure reduction indicated that ≥50% of patients achieved this, with improved functional ability. Seizure freedom rate was generally <10%. Six studies with 47 patients provided IPD. The mean ages at epilepsy onset and CMN DBS were 3.9 ± 4.5 years and 17.4 ± 8.8 years, respectively. Nineteen of 41 (46.3%) patients had positive MRI findings. Seizure types included atypical absence in 39 (83.0%) patients, generalized tonic-clonic in 32 (68.1%), tonic in 22 (46.8%), and atonic in 20 (42.6%). Thirty-eight (80.9%) patients experienced ≥50% reduction in seizure frequency, and only 3 (6.4%) experienced seizure freedom. The mean seizure reduction was 62.9% ± 31.2% overall. Quality of life improved in 30/34 (88.2%) and was unchanged in the remainder (11.8%). The complication rate was 2/41 (4.9%). The mean length of follow-up was 19.8 ± 26.1 months (IQR: 4-18 months).
CONCLUSION
Limited data indicate that DBS of the CMN may be effective and safe for people with LGS.
Identifiants
pubmed: 36700706
doi: 10.1227/neu.0000000000002280
pii: 00006123-202304000-00007
doi:
Types de publication
Systematic Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
703-715Informations de copyright
Copyright © Congress of Neurological Surgeons 2022. All rights reserved.
Références
Camfield PR. Definition and natural history of Lennox Gastaut syndrome. Epilepsia. 2011;52:3-9.
Asadi-Pooya AA. Lennox-Gastaut syndrome: a comprehensive review. Neurol Sci. 2018;39(3):403-414.
Gastaut H, Roger J, Soulayrol R, et al. Epileptic encephalopathy of children with diffuse slow spikes and waves (alias “petit mal variant”) or Lennox syndrome. Ann Pediatr. 1966;13(8):489-499.
Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia. 1989;30(4):389-399.
Heiskala H. Community based study of Lennox Gastaut syndrome. Epilepsia. 1997;38(5):526-531.
Trevathan E, Murphy CC, Yeargin Allsopp M. Prevalence and descriptive epidemiology of Lennox Gastaut syndrome among Atlanta children. Epilepsia. 1997;38(12):1283-1288.
Kramer U, Nevo Y, Neufeld MY, Fatal A, Leitner Y, Harel S. Epidemiology of epilepsy in childhood: a cohort of 440 consecutive patients. Pediatr Neurol. 1998;18(1):46-50.
Goldsmith IL, Zupanc ML, Buchhalter JR. Long term seizure outcome in 74 patients with Lennox–Gastaut syndrome: effects of incorporating MRI head imaging in defining the cryptogenic subgroup. Epilepsia. 2000;41(4):395-399.
Crumrine PK. Lennox-Gastaut syndrome. J child Neurol. 2002;17(1 suppl):S70-S75.
Asadi-Pooya AA, Sharifzade M. Lennox–Gastaut syndrome in south Iran: electro-clinical manifestations. Seizure. 2012;21(10):760-763.
Cavazzuti GB. Epidemiology of different types of epilepsy in school age children of Modena, Italy. Epilepsia. 1980;21(1):57-62.
Strzelczyk A, Schubert-Bast S, Simon A, Wyatt G, Holland R, Rosenow F. Epidemiology, healthcare resource use, and mortality in patients with probable Lennox-Gastaut syndrome: a population-based study on German Health Insurance Data. Epilepsy Behav. 2021;115:107647.
Hancock EC, Cross JH. Treatment of Lennox-Gastaut syndrome. Cochrane Database Syst Rev. 2013;2013(2):CD003277.
Arzimanoglou A, French J, Blume WT, et al. Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology. Lancet Neurol. 2009;8(1):82-93.
Douglass LM, Salpekar J. Surgical options for patients with Lennox-Gastaut syndrome. Epilepsia. 2014;55:21-28.
Lee YJ, Kang H-C, Lee JS, et al. Resective pediatric epilepsy surgery in Lennox-Gastaut syndrome. Pediatrics. 2010;125(1):e58-e66.
Kang JW, Eom S, Hong W, et al. Long-term outcome of resective epilepsy surgery in patients with Lennox-Gastaut syndrome. Pediatrics. 2018;142(4):e20180449.
Wyllie E, Lachhwani DK, Gupta A, et al. Successful surgery for epilepsy due to early brain lesions despite generalized EEG findings. Neurology. 2007;69(4):389-397.
Thirunavu V, Du R, Wu JY, Berg AT, Lam SK. The role of surgery in the management of Lennox–Gastaut syndrome: a systematic review and meta analysis of the clinical evidence. Epilepsia. 2021;62(4):888-907.
Khan M, Paktiawal J, Piper RJ, Chari A, Tisdall MM. Intracranial neuromodulation with deep brain stimulation and responsive neurostimulation in children with drug-resistant epilepsy: a systematic review. J Neurosurg Pediatr. 2021;1(aop):1-10.
Benbadis SR, Geller E, Ryvlin P, et al. Putting it all together: options for intractable epilepsy. Epilepsy Behav. 2018;88:33-38.
Velasco F, Saucedo-Alvarado PE, Reichrath A, Valdés-Quiroz H, Aguado-Carrillo G, Velasco AL. Centromedian nucleus and epilepsy. J Clin Neurophysiol. 2021;38(6):485-493.
Valentín A, García Navarrete E, Chelvarajah R, et al. Deep brain stimulation of the centromedian thalamic nucleus for the treatment of generalized and frontal epilepsies. Epilepsia. 2013;54(10):1823-1833.
Velasco F, Velasco A, Velasco M, Jimenez F, Carrillo-Ruiz J, Castro G. Deep brain stimulation for treatment of the epilepsies: the centromedian thalamic target. Acta Neurochir Suppl. 2013;97(pt 2):337-342.
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg. 2021;88:105906.
Page MJ, Moher D, Bossuyt PM, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. Bmj. 2021;372:n160.
Shlobin NA, Moher D. Commentary: preferred reporting items for systematic reviews and meta-analyses 2020 statement: what neurosurgeons should know. Neurosurgery. 2021;89(5):E267-E268.
Stewart LA, Clarke M, Rovers M, et al. Preferred reporting items for a systematic review and meta-analysis of individual participant data: the PRISMA-IPD statement. JAMA. 2015;313(16):1657-1665.
World Bank Country and Lending Groups. https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups . Accessed June 1, 2022.
Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. Bmj. 2008;336(7650):924-926.
Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. Bmj. 2016;355:i4919.
Alcala-Zermeno JL, Gregg NM, Wirrell EC, et al. Centromedian thalamic nucleus with or without anterior thalamic nucleus deep brain stimulation for epilepsy in children and adults: a retrospective case series. Seizure. 2021;84:101-107.
Cukiert A, Cukiert CM, Burattini JA, Mariani PP. Seizure outcome during bilateral, continuous, thalamic centromedian nuclei deep brain stimulation in patients with generalized epilepsy: a prospective, open-label study. Seizure. 2020;81:304-309.
Dalic LJ, Warren AEL, Bulluss KJ, et al. DBS of thalamic centromedian nucleus for Lennox–Gastaut syndrome (ESTEL trial). Ann Neurol. 2022;91(2):253-267.
Passamonti C, Mancini F, Cesaroni E, et al. Deep brain stimulation in patients with long history of drug resistant epilepsy and poor functional status: outcomes based on the different targets. Clin Neurol Neurosurg. 2021;208:106827.
Son B-C, Shon YM, Choi J-G, et al. Clinical outcome of patients with deep brain stimulation of the centromedian thalamic nucleus for refractory epilepsy and location of the active contacts. Stereotactic Funct Neurosurg. 2016;94(3):187-197.
Velasco F, Velasco M, Jimenez F, Velasco AL, Rojas B, Perez ML. Centromedian nucleus stimulation for epilepsy clinical, electroencephalographic, and behavioral observations. Thalamus Relat Syst. 2002;1(4):387-398.
Velasco AL, Velasco F, Jiménez F, et al. Neuromodulation of the centromedian thalamic nuclei in the treatment of generalized seizures and the improvement of the quality of life in patients with Lennox–Gastaut syndrome. Epilepsia. 2006;47(7):1203-1212.
Warren AEL, Dalic LJ, Thevathasan W, Roten A, Bulluss KJ, Archer J. Targeting the centromedian thalamic nucleus for deep brain stimulation. J Neurol Neurosurg Psychiatry. 2020;91(4):339-349.
Warren AE, Dalic LJ, Bulluss KJ, BAppSci AR, Thevathasan W, Archer JS. The optimal target and connectivity for deep brain stimulation in Lennox–Gastaut syndrome. Ann Neurol. 2022;92(1):61-74.
Yang JC, Bullinger KL, Isbaine F, et al. Centromedian thalamic deep brain stimulation for drug-resistant epilepsy: single-center experience. J Neurosurg. 2022;1(aop):1-10.
Lancman G, Virk M, Shao H, et al. Vagus nerve stimulation vs. corpus callosotomy in the treatment of Lennox–Gastaut syndrome: a meta-analysis. Seizure. 2013;22(1):3-8.
Gallop K, Wild D, Nixon A, Verdian L, Cramer JA. Impact of Lennox-Gastaut Syndrome (LGS) on health-related quality of life (HRQL) of patients and caregivers: literature review. Seizure. 2009;18(8):554-558.
Kwon CS, Schupper AJ, Fields MC, et al. Centromedian thalamic responsive neurostimulation for Lennox-Gastaut epilepsy and autism. Ann Clin Translational Neurol. 2020;7(10):2035-2040.
Shlobin NA, Campbell JM, Rosenow JM, Rolston JD. Ethical considerations in the surgical and neuromodulatory treatment of epilepsy. Epilepsy Behav. 2022;127:108524.
Shlobin NA, Sheldon M, Lam S. Informed consent in neurosurgery: a systematic review. Neurosurg Focus. 2020;49(5):E6.
Sisterson ND, Wozny TA, Kokkinos V, Constantino A, Richardson RM. Closed-loop brain stimulation for drug-resistant epilepsy: towards an evidence-based approach to personalized medicine. Neurotherapeutics. 2019;16(1):119-127.
Shlobin NA, Clark JR, Hoffman SC, Hopkins BS, Kesavabhotla K, Dahdaleh NS. Patient education in neurosurgery: part 2 of a systematic review. World Neurosurg. 2021;147:190.e1-201.e1.
Shlobin NA, Clark JR, Hoffman SC, Hopkins BS, Kesavabhotla K, Dahdaleh NS. Patient education in neurosurgery: part 1 of a systematic review. World Neurosurg. 2021;147:202.e1-214.e1.
Shlobin NA, Rosenow JM. Ethical considerations in the implantation of neuromodulatory devices. Neuromodulation. 2022;25(2):222-231.
Bourgeois BFD, Douglass LM, Sankar R. Lennox Gastaut syndrome: a consensus approach to differential diagnosis. Epilepsia. 2014;55:4-9.
Aghaei-Lasboo A, Fisher RS. Methods for measuring seizure frequency and severity. Neurol Clin. 2016;34(2):383-394.